Uptake Medical is focused on the development and commercialization of InterVapor, a non-surgical, endoscopic lung volume reduction system that uses the body’s natural healing processes without leaving implants or foreign material in the lung. InterVapor is the company’s first product and in clinical studies has demonstrated improvements in breathing function, exercise capacity and quality of life. The company received CE mark approval for InterVapor and completed the first commercial use in Germany, and also secured TGA approval to market the product in Australia. Uptake Medical is actively executing commercial strategies to establish InterVapor as a standard of care for severe emphysema. The company is headquartered in Tustin, Calif., and emphasizes continued commercialization and market expansion following regulatory clearances. Uptake Medical is an interventional pulmonology company that develops medical technologies to treat lung diseases including emphysema, a form of COPD. Its core product is a minimally invasive, bronchoscopic catheter-based procedure called Bronchoscopic Thermal Vapor Ablation (BTVA). BTVA delivers thermal vapor to emphysematous lung tissue to achieve lung volume reduction. The therapy causes diseased areas to reduce in volume, allowing remaining healthy lung to expand and function more normally. The company plans to use new capital to obtain the CE mark and introduce BTVA outside the U.S. Uptake Medical has also begun its approval cycle with the FDA in the U.S. and is based in Seattle, Washington. Uptake Medical is an early-stage medical device company developing a bronchoscopic lung volume reduction (BLVR) therapy for emphysema and COPD. Its next-generation interventional pulmonology approach is designed to measurably improve lung function and patient quality of life while avoiding the risks and costs associated with surgery, endobronchial glues, valves and occluders. The company is privately held and based in Seattle. Uptake closed a $9 million Series A equity financing to fund pre-clinical development of its proprietary BLVR technology and to build staff prior to clinical trials. Management and investors position the therapy as a simpler, safer and more cost-effective option intended to be widely accessible to emphysema patients. The article cites the American Lung Association that emphysema affects about three million people in the U.S. and 16 million worldwide.

Total raised

$27M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2010